IMPaCT 2.0

7.项目总结 非洲裔美国人(AA)比美国任何种族和民族都更有可能罹患癌症并死于癌症 美国(美国)。在过去的二十年里，越来越多的人关注农业协会参与 癌症临床试验(CCT)，以解决这一不成比例的癌症负担；然而，AA继续 在有条件现金援助中代表性不足。缺少AAS参与CCTS降低了以下结果的概括性 审判。如果AA在有条件现金援助中的代表性仍然偏低，其影响包括澄清 癌症结局中长期存在的健康差距的根本原因。有一大堆 详细说明美国儿科协会参与试验的障碍的科学，包括进入专门护理中心的限制 在哪里进行试验，相互竞争的工作义务，以及对临床研究的恐惧和不信任。尽管 这些障碍，从本质上讲，AAA参与CCT或其他类型研究的意愿并不比 其他种族或民族。在参与意愿方面没有差异表明，持续的 事实上，收入差距可能是因为AAS提供的参与机会比白人少 闭路电视。尽管许多干预措施都集中在增加AA意愿的方法上 参与，或许应该把重点放在增加AAA参与的机会上 闭路电视。我们建议采用IMPACT患者导航模型，并试行临床试验导航器计划， Impact 2.0，在莫尔豪斯医疗保健(MH)和格雷迪医院(Grady)，最大的安全网之一 全国的医院。我们建议使用基于移动平板电脑的临床应用来增强患者导航模型 试验跟踪系统(CTTS)(使用i2b2软件)，以促进再生障碍性贫血患者更多的参与 关于参与有条件现金转移的机会和解决这两个机构在研究基础设施方面的不足 机构。利用定性方法，我们将在以下地点确定AA招聘的障碍和促进者 MH/Grady(特定目标1)，并将这些发现纳入调整后的临床试验导航(CTN) 集成移动平板电脑CTTS的型号(特定目标2)，我们将在MH/Grady实施Impact 2.0 乳腺癌和前列腺癌临床，并在一组试验前/试验后设计中评估可行性和 可接受性(具体目标3)。

7. PROJECT SUMMARY African Americans (AAs) are more likely to develop and die from cancer than any racial and ethnic group in the United States (U.S.). Over the past two decades, there has been an increased focus on participation of AAs in cancer clinical trials (CCTs) to address this disproportionate burden of cancer; however AAs continue to be underrepresented in CCTs. The dearth of AAs participating in CCTs diminishes the generalizability of results of trials. If AAs remain underrepresented in CCTs, the implications include slower progress in elucidating the underlying causes of long-standing health disparities in cancer outcomes. There is an extensive body of science detailing trial participation barriers among AAs, including limited access to specialty care centers where trials are conducted, competing work obligations, and fear and mistrust of clinical research. Despite these barriers, AAs are, inherently, no less willing to participate in CCTs or other types of research studies than other racial or ethnic groups. The absence of differences in willingness to participate suggests that persistent disparities in accrual may, in fact, be due to AAs being offered fewer opportunities than whites to participate in CCTs. Although many interventions have focused on approaches to increase the willingness of AAs to participate, perhaps efforts should be focused on increasing the opportunities among AAs to participate in CCTs. We propose to adapt the IMPaCT patient navigation model and pilot a clinical trials navigator program, IMPaCT 2.0, at Morehouse Healthcare (MH) and Grady Hospital (Grady), one of the largest safety-net hospitals in the nation. We propose to enhance the patient navigation model with a mobile tablet-based clinical trial tracking system (CTTS) (using i2b2 software) to facilitate increased engagement among AA patients regarding CCT participation opportunities and to address deficits in the research infrastructure at these two institutions. Utilizing a qualitative approach, we will identify those barriers and facilitators to AA recruitment at MH/Grady (Specific Aim 1) and incorporate those findings into an adapted clinical trials navigation (CTN) model with an integrated mobile tablet CTTS (Specific Aim 2)., We will implement IMPaCT 2.0 at MH/Grady breast and prostate cancer clinics and evaluate, in a one-group, pre-/post-test design, the feasibility and acceptability (Specific Aim 3).